ECOG-ACRIN Cancer Research Group
US cooperative group that pairs a therapy group with an imaging group; its E1910 trial moved blinatumomab into frontline leukaemia treatment.
Merger (2012) of the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network. E1910 showed adding blinatumomab consolidation improves survival in MRD-negative B-ALL, leading to the 2024 label. Also runs TMIST (tomosynthesis vs digital mammography screening) and the ECOG performance status scale.
- NCTN cooperative group
- E1910 blinatumomab
- TMIST screening trial
- Imaging biomarker trials
Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.
Mitchell Schnall is the radiologist who brought imaging research into the ECOG-ACRIN cooperative group.
Peter O'Dwyer is a GI oncologist who co-leads ECOG-ACRIN, one of the NCI's national trial networks.
Myeloma trialist who led venetoclax and quadruplet studies and helped define MRD response criteria.
Pages like this
not linked directly; found by shared links- PairingBlinatumomab added to frontline chemotherapy
Shares ECOG-ACRIN E1910, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab, Acute lymphoblastic leukaemia.
- InstitutionSWOG Cancer Research Network
Shares Follow every trial participant for 30 years through registry linkage, A publicly held library of investigational drugs available for academic combination trials, A fixed share of trial-group funding for getting proven care to patients, Older and multimorbid patients are excluded and undertreated.
- IdeaA trials fund reserved for older and multimorbid patients
Shares A fixed share of trial-group funding for getting proven care to patients, Older and multimorbid patients are excluded and undertreated, Trials do not represent the people who get cancer.
- TargetCD3
Shares Mark R. Litzow, ECOG-ACRIN E1910, ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission, Blinatumomab.
- IdeaCommunity health workers and trusted local organisations paid to recruit for trials
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaAt least a third of pivotal-trial sites in community and rural settings
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaRemove blanket exclusions for mental illness and dementia; support consent instead
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaMobile research units bring trial visits to rural towns
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, National Cancer Institute (NIH).